Entering text into the input field will update the search result below

Icelandic biosimilars developer Alvotech initiated with a hold rating by Deutsche Bank

Jul. 01, 2022 12:50 PM ETAlvotech (ALVO)By: Anuron Mitra, SA News Editor1 Comment
  • Deutsche Bank research initiated biosimilars developer Alvotech (NASDAQ:ALVO) with a hold rating, citing risks related to pending regulatory decisions and competitors.
  • Deutsche Bank analyst Emmanuel Papadakis gave ALVO stock a price target of $10, representing a 21.8% upside to ALVO's last close.

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

This analyst is out to lunch.
He fails to understand that you bet on the jockey when investing in these Biosimilar drug companies.
The jockey being the CEO.
Not to mention Oaktree (Howard Marks) is behind the deal
From the start.

About ALVO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Arcellx, Inc.
MoonLake Immunotherapeutics
Biohaven Ltd.
Intellia Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.